Pre-Analytical Error Cost Analysis of 10,732 Contaminated Urine Culture Samples

Basit Öğe Kaydı
dc.authoridEKER, PINAR/0000-0001-6514-8047en_US
dc.contributor.authorEker, Pınar
dc.date.accessioned2024-07-12T21:37:30Z
dc.date.available2024-07-12T21:37:30Z
dc.date.issued2022en_US
dc.department[Belirlenecek]en_US
dc.description.abstractBackground: Unlike other pre-analytical (PA) phase errors, in our country Social Security Institution (SSI) reimburses urine samples rejected due to contamination in the form of a finalized test. The primary purpose was to estimate the direct financial loss created by contaminated urine sampling. We want to encourage its prioritization among corrective and preventive actions of laboratory PA management. Methods: We examined the urine samples which were sent to Istanbul Anatolian North Central Laboratory retrospectively. The central laboratory serves the community of 6,400-bed hospitals. We made direct financial loss calculations with material-, labor-, and waste-related financial elements. Results: We rejected 10,732 of 138,834 samples due to contamination. With the 2019 Euro Index, the cost for each urine sample rejected due to contamination was calculated as euro 2.98. Conclusions: It is the first cost study where the prices are in human resources, material, waste cost, and the amount reimbursed by SSI as direct cost elements per rejection sample. Highlighting the cost elements in establishing health policies predicted due to their striking feature may contribute to their prioritization in corrective and preventive actions. The urine culture test is the most commonly performed bacterial culture test. The determination of financial loss predicted that it would also reduce antibiotic resistance in healthcare by providing financial resource threshold information to develop improved methods. In addition, it will inspire new additions to the existing few detailed pre-analytical error cost studies.en_US
dc.identifier.doi10.7754/Clin.Lab.2021.210828
dc.identifier.endpage633en_US
dc.identifier.issn1433-6510
dc.identifier.issue3en_US
dc.identifier.pmid35254043en_US
dc.identifier.scopus2-s2.0-85125965221en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage627en_US
dc.identifier.urihttps://doi.org/10.7754/Clin.Lab.2021.210828
dc.identifier.urihttps://hdl.handle.net/20.500.12415/6820
dc.identifier.volume68en_US
dc.identifier.wosWOS:000757490200001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherClin Lab Publen_US
dc.relation.ispartofClinical Laboratoryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY04162
dc.subjectPre-Analytical Phaseen_US
dc.subjectCosten_US
dc.subjectContaminated Urine Sampleen_US
dc.titlePre-Analytical Error Cost Analysis of 10,732 Contaminated Urine Culture Samplesen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu